AAAAAA
Results:
1-12
|
Results: 12
Authors:
Schooley, RT
Clumeck, N
Haubrich, R
Thompson, M
Danner, SA
van Der Ende, ME
Sereni, D
Antunes, F
Blake, D
Myers, RE
Tisdale, M
Millard, J
Mustafa, N
Nacci, P
Citation: Rt. Schooley et al., A dose-ranging study to evaluate the antiretroviral activity and safety ofamprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience, ANTIVIR TH, 6(2), 2001, pp. 89-96
Authors:
Emilie, D
Burgard, M
Lascoux-Combe, C
Laughlin, M
Krzysiek, R
Pignon, C
Rudent, A
Molina, JM
Livrozet, JM
Souala, F
Chene, G
Grangeot-Keros, L
Galanaud, P
Sereni, D
Rouzioux, C
Citation: D. Emilie et al., Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study, AIDS, 15(11), 2001, pp. 1435-1437
Authors:
Harmouche, H
Bourgarit, A
Farge, D
Sereni, D
Citation: H. Harmouche et al., A less-threatening vertebral lytic lesion, REV MED IN, 22(9), 2001, pp. 886-888
Authors:
Sereni, D
Citation: D. Sereni, Unhappy clinicians, REV MED IN, 22(6), 2001, pp. 518-518
Authors:
Krzysiek, R
Rudent, A
Bouchet-Delbos, L
Foussat, A
Boutillon, C
Portier, A
Ingrand, D
Sereni, D
Galanaud, P
Grangeot-Keros, L
Emilie, D
Citation: R. Krzysiek et al., Preferential and persistent depletion of CCR5(+) T-helper lymphocytes withnonlymphoid homing potential despite early treatment of primary HIV infection, BLOOD, 98(10), 2001, pp. 3169-3171
Authors:
Girard, PM
Pegram, PS
Diquet, B
Anderson, R
Raffi, F
Tubiana, R
Sereni, D
Boerner, D
Citation: Pm. Girard et al., Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection:Pharmacokinetics, tolerability, and efficacy, J ACQ IMM D, 23(3), 2000, pp. 227-235
Authors:
Garrigue, I
Pellegrin, I
Hoen, B
Dumon, B
Harzic, M
Schrive, MH
Sereni, D
Fleury, H
Citation: I. Garrigue et al., Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA, AIDS, 14(18), 2000, pp. 2851-2855
Authors:
El Guedj, M
Zamfir, RM
Brice, P
Sereni, D
Farge, D
Citation: M. El Guedj et al., Multiple myeloma stage II - Possibly in association with idiopathic aplasia, REV MED IN, 21, 2000, pp. 395S-398S
Authors:
Molina, JM
Ferchal, F
Rancinan, C
Raffi, F
Rozenbaum, W
Sereni, D
Morlat, P
Journot, V
Decazes, JM
Chene, G
Citation: Jm. Molina et al., Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients, J INFEC DIS, 182(2), 2000, pp. 599-602
Authors:
Haubrich, R
Thompson, M
Schooley, R
Lang, W
Stein, A
Sereni, D
van der Ende, ME
Antunes, F
Richman, D
Pagano, G
Kahl, L
Fetter, A
Brown, DJ
Clumeck, N
Citation: R. Haubrich et al., A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviralexperience, AIDS, 13(17), 1999, pp. 2411-2420
Authors:
Sereni, D
Tubiana, R
Lascoux, C
Katlama, C
Taulera, O
Bourque, A
Cohen, A
Dvorchik, B
Martin, RR
Tournerie, C
Gouyette, A
Schechter, PJ
Citation: D. Sereni et al., Pharmacokinetics and tolerability of intravenous Trecovirsen (GEM (R) 91),an antisense phosphorothioate oligonucleotide, in HIV-positive subjects, J CLIN PHAR, 39(1), 1999, pp. 47-54
Authors:
Hoen, B
Dumon, B
Harzic, M
Venet, A
Dubeaux, B
Lascoux, C
Bourezane, Y
Ragnaud, JM
Bicart-See, A
Raffi, F
Beauvais, L
Fleury, H
Sereni, D
Citation: B. Hoen et al., Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial, J INFEC DIS, 180(4), 1999, pp. 1342-1346
Risultati:
1-12
|